YieldMax's MSTR Is A Nightmare ETF, Despite Dreamy Dividends
247wallst.com
Pharvaris N.V.PHVSNASDAQ
Loading
Alerts
Want to monitor PHVS?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor PHVSWant to monitor PHVS?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor PHVSPharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.